Solid Biosciences (SLDB) Total Current Liabilities (2017 - 2024)
Historic Total Current Liabilities for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to $22.9 million.
- Solid Biosciences' Total Current Liabilities rose 4449.92% to $22.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $22.9 million, marking a year-over-year increase of 4449.92%. This contributed to the annual value of $14.5 million for FY2023, which is 3550.29% down from last year.
- As of Q3 2024, Solid Biosciences' Total Current Liabilities stood at $22.9 million, which was up 4449.92% from $14.7 million recorded in Q2 2024.
- Solid Biosciences' 5-year Total Current Liabilities high stood at $24.5 million for Q4 2020, and its period low was $12.9 million during Q1 2020.
- Its 5-year average for Total Current Liabilities is $18.8 million, with a median of $20.3 million in 2023.
- Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 7724.38% in 2021, then plummeted by 3550.29% in 2023.
- Quarter analysis of 5 years shows Solid Biosciences' Total Current Liabilities stood at $24.5 million in 2020, then decreased by 3.59% to $23.6 million in 2021, then decreased by 4.63% to $22.5 million in 2022, then plummeted by 35.5% to $14.5 million in 2023, then surged by 57.43% to $22.9 million in 2024.
- Its Total Current Liabilities was $22.9 million in Q3 2024, compared to $14.7 million in Q2 2024 and $14.3 million in Q1 2024.